Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Susana Bezares"'
Autor:
Ariadna Tibau, M. Teresa Martínez, Manuel Ramos, Luis De La Cruz-Merino, Ana Santaballa, Miriam O’Connor, Noelia Martínez-Jañez, Fernando Moreno, Isaura Fernández, Juan Antonio Virizuela, Jesús Alarcón, Juan de La Haba-Rodríguez, Pedro Sánchez-Rovira, Cinta Rosa Albacar, Coralia Bueno Muiño, Catherine Kelly, Maribel Casas, Susana Bezares, Libertad Rosell, Joan Albanell
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression-free survival (PFS) compared with placebo/fulvestrant in postmenopausal women with HR+/HER2− advanced breast cancer (ABC). Objective: We assessed health-re
Externí odkaz:
https://doaj.org/article/4398b5e7e69c43578d588e0c150efdbd
Autor:
Nerea Fernández de Larrea-Baz, Beatriz Pérez-Gómez, Ángel Guerrero-Zotano, Ana María Casas, Begoña Bermejo, José Manuel Baena-Cañada, Silvia Antolin, Pedro Sánchez-Rovira, Manuel Ramos Vázquez, José Ángel Garcia-Sáenz, Antonio Antón, Montserrat Muñoz, Ana de Juan, Carlos Jara, José Ignacio Chacón, Angels Arcusa, Miguel Gil-Gil, Encarna Adrover, Amparo Oltra, Joan Brunet, Sonia González, Susana Bezares, Virginia Lope, Miguel Martín, Marina Pollán
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-13 (2020)
Abstract This study evaluates the impact of breast cancer (BC) in health related quality of life (HRQL) and in psychological distress (PD) during the initial phases of the disease and looks for contributing factors. A multicentric case-control study,
Externí odkaz:
https://doaj.org/article/33b3d22231de42aba2eaca043fcc939b
Autor:
Virginia Lope, Angel Guerrero-Zotano, Emma Ruiz-Moreno, Begoña Bermejo, Silvia Antolín, Álvaro Montaño, José Manuel Baena-Cañada, Manuel Ramos Vázquez, Nerea Fernández de Larrea-Baz, José Ignacio Chacón, José Angel García-Sáenz, Clara Olier, Montserrat Muñoz, Antonio Antón, Pedro Sánchez Rovira, Angels Arcusa Lanza, Sonia González, Amparo Oltra, Joan Brunet, Joaquín Gavilá Gregori, María Teresa Martínez, Lourdes Calvo, Libertad Rosell, Susana Bezares, Roberto Pastor-Barriuso, Beatriz Pérez-Gómez, Miguel Martín, Marina Pollán
Publikováno v:
Cancers, Vol 14, Iss 19, p 4705 (2022)
Breast cancer (BC) survivors are advised to follow the WCRF/AICR cancer prevention recommendations, given their high risk of developing a second tumour. We aimed to explore compliance with these recommendations in BC survivors and to identify potenti
Externí odkaz:
https://doaj.org/article/74efbdccd0e148af99a4b0494bba2f14
Autor:
Aurélie S. Cazet, Mun N. Hui, Benjamin L. Elsworth, Sunny Z. Wu, Daniel Roden, Chia-Ling Chan, Joanna N. Skhinas, Raphaël Collot, Jessica Yang, Kate Harvey, M. Zahied Johan, Caroline Cooper, Radhika Nair, David Herrmann, Andrea McFarland, Niantao Deng, Manuel Ruiz-Borrego, Federico Rojo, José M. Trigo, Susana Bezares, Rosalía Caballero, Elgene Lim, Paul Timpson, Sandra O’Toole, D. Neil Watkins, Thomas R. Cox, Michael S. Samuel, Miguel Martín, Alexander Swarbrick
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-18 (2018)
Stromal cell recruitment, activation and crosstalk with cancer cells is poorly understood. Here, the authors demonstrate that cancer cell-derived Hedgehog ligand triggers stromal remodeling that in turn induces a cancer-stem-cell like, drug-resistant
Externí odkaz:
https://doaj.org/article/39594924f30743e1a45878b7f73d9070
Autor:
Luis de la Cruz-Merino, María Gion, Josefina Cruz-Jurado, Vanesa Quiroga, Raquel Andrés, Fernando Moreno, Jose L. Alonso-Romero, Manuel Ramos, Esther Holgado, Javier Cortés, Elena López-Miranda, Fernando Henao-Carrasco, Natalia Palazón-Carrión, Luz M. Rodríguez, Isaac Ceballos, Maribel Casas, Sara Benito, Massimo Chiesa, Susana Bezares, Rosalia Caballero, Carlos Jiménez-Cortegana, Víctor Sánchez-Margalet, Federico Rojo
Publikováno v:
Cancers, Vol 13, Iss 21, p 5432 (2021)
The PANGEA-Breast trial evaluated a new chemo-immunotherapeutic combination that would synergistically induce long-term clinical benefit in HER2-negative advanced breast cancer patients. Treatment consisted of 21-day cycles of 200 mg of pembrolizumab
Externí odkaz:
https://doaj.org/article/f493f8a297a3479694a4af97c2b66c7c
Autor:
Silvia Antolin Novoa, César A Rodríguez, Josefina Cruz, Sara López-Tarruella, Ariadna Tibau, Encarna Adrover, Ana Miguel, Mireia Margelí, Purificación Martínez, María Hernández, Antonio Antón, Álvaro Rodríguez-Lescure, Catalina Falo, Isabel Álvarez, Diego Malón, Raquel Andrés, José L Alonso-Romero, César Gómez, J. José Illaramendi, Ruth Campo, Juan José Miralles, Susana Bezares, Federico Rojo, Angel Guerrero-Zotano
Publikováno v:
Cancer Research. 83:P4-07
Background: Triple negative breast cancer (TNBC) is well known for its more aggressive course and poorer prognosis compared to other BC subtypes. RegistEM study provides real world data to understand the distribution of BC subtypes in the advanced se
Autor:
Isabel Álvarez, Angel Guerrero-Zotano, Ariadna Tibau, Catalina Falo, María Hernández, Ana Miguel, Raquel Andrés, Álvaro Rodríguez-Lescure, Miguel Corbellas, Sara López-Tarruella, Purificación Martínez, Cesar A Rodríguez, Diego Malón, María Marin, Mª José Echarri, Antonio Antón, Josefina Cruz, Diana Moreno, J. Ignacio Chacón, Ruth Campo, Andrea Blasco, Susana Bezares, Federico Rojo, Silvia Antolin
Publikováno v:
Cancer Research. 83:P4-07
Background: HER2-low breast cancer (BC) is a new therapeutic entity, but it is uncertain if this subgroup of BC differs from HER2-negative tumors in clinical characteristics, prognosis, and response to therapy. The objective is to describe the clinic
Autor:
Sara López-Tarruella, Angel Guerrero-Zotano, Josefina Cruz, Silvia Antolin Novoa, Purificación Martínez, María Hernández, César A Rodríguez, J. Ignacio Chacón, Ariadna Tibau, Catalina Falo, Álvaro Rodríguez-Lescure, Mireia Margelí, Sonia Servitja, Raquel Andrés, María Galán-Gramaje, Encarna Adrover, Ana Miguel, Rafael Villanueva, Silvia Varela, Ruth Campo, Mª José Escudero, Susana Bezares, Federico Rojo, Isabel Álvarez
Publikováno v:
Cancer Research. 83:P4-07
Background: Over the last years, the treatment of HER2-positive (HER2+) breast cancer (BC) patients (pts) has been changing because of the development of new anti-HER2 agents. In the current analysis, we describe the features, treatment patterns, pro
Autor:
Txomin Pérez-Bilbao, María Alonso-Dueñas, Alejandro F. San Juan, Susana Bezares, Lucía Gil Herrero, Marina Pollán, Pablo González-Frutos, Ana B. Peinado, Soraya Casla-Barrio
Publikováno v:
Journal of Applied Physiology. 133:443-448
The aim of this study was to evaluate the capacity to return to competition of a 28-yr-old female 400-m hurdle elite athlete after a diagnosis of breast cancer. The study lasted 14 mo after diagnosis. She was tested four times (T1–T4) to measure bo
Autor:
Carolina Donat-Vargas, Ángel Guerrero-Zotano, Virginia Lope, Begoña Bermejo, Ana Casas, José Manuel Baena-Cañada, Silvia Antolín, Pedro Sánchez-Rovira, Antonio Antón, José Ángel Garcia-Saénz, Manuel Ramos, Montserrat Muñoz, Ana de Juan, Carlos Jara Sánchez, José Ignacio Chacón, Miguel Gil-Gil, Raquel Andrés Conejero, Antonio Llombart, Susana Bezares, Nerea Fernández de Larrea-Baz, Beatriz Pérez-Gómez, Miguel Martín, Marina Pollán
Publikováno v:
EUROPEAN JOURNAL OF CLINICAL NUTRITION
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Consejo Superior de Investigaciones Científicas (CSIC)
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Consejo Superior de Investigaciones Científicas (CSIC)
The Epi-GEICAM study comprises 1017 invasive BC cases matched with controls of similar age (49 +/- 9 years) and residence. Diet and OO consumption were collected through a validated food frequency questionnaire. 75% of women referred OO, common (refi